{
  "author": {
    "name": "Dea Belazi",
    "webUrl": "/author/profile/dea-belazi/",
    "description": "",
    "imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
    "estimate": 1,
    "social": [],
    "articles": [
      {
        "uri": "/2020/04/28/impact-of-cms-part-proposal-on-specialty-drug-costs-what-brokers-should-know/",
        "title": "Impact of CMS Part D proposal on specialty drug costs: What brokers should know",
        "byline": "Dea Belazi",
        "kicker": "Expert Opinion",
        "prettyDate": "April 28, 2020",
        "timeToRead": "6 minute",
        "image": {
          "uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2019/06/Opioids-Pills-Article-201906052355.jpg",
          "width": "620",
          "height": "372"
        },
        "authors": [
          {
            "webUrl": "/author/profile/dea-belazi/",
            "name": "Dea Belazi"
          }
        ],
        "kickerNode": [
          {
            "uri": "/expert-opinion/",
            "sectionName": "Expert Opinion"
          }
        ],
        "summary": "Costs of managing chronic disease is top of mind for employers, and the CMS's proposed legislation could have a major impact.",
        "body": null
      }
    ]
  }
}